Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncternal Therapeutics Inc (ONCT)
NASDAQ:ONCT
RESEARCH TOOLSreports
Holding ONCT?
Track your performance easily
ONCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.03 - $13.14
Previous Close$1.14
Volume22.02K
Average Volume (3M)97.99K
Market Cap
$3.37M
Enterprise Value-$11.01M
Total Cash (Recent Filing)$14.58M
Total Debt (Recent Filing)$191.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.69
Shares Outstanding2,959,645
10 Day Avg. Volume104,392
30 Day Avg. Volume97,987
Standard Deviation0.27
R-Squared0.07
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.50
Enterprise Value/Gross Profit-14.03
Enterprise Value/Ebitda0.43
Forecast
1Y Price Target
$2.00Price Target Upside75.44% Upside
Rating ConsensusHold
Number of Analyst Covering2
Oncternal Therapeutics News
PremiumCompany Announcements
Oncternal Therapeutics Reports Q3 2024 Earnings
PremiumCompany Announcements
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes
PremiumCompany Announcements
Oncternal Therapeutics Restructures Amid Clinical Setbacks
Ownership Overview
42.14% Insiders
5.88% Mutual Funds
1.71% Other Institutional Investors
45.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ONCT FAQ
What was Oncternal Therapeutics Inc’s price range in the past 12 months?
Oncternal Therapeutics Inc lowest stock price was $1.03 and its highest was $13.14 in the past 12 months.
What is Oncternal Therapeutics Inc’s market cap?
Currently, no data Available
When is Oncternal Therapeutics Inc’s upcoming earnings report date?
Oncternal Therapeutics Inc’s upcoming earnings report date is Mar 06, 2025 which is in 101 days.
How were Oncternal Therapeutics Inc’s earnings last quarter?
Oncternal Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$2.86 earnings per share for the quarter, beating the consensus estimate of -$3.22 by $0.36.
Is Oncternal Therapeutics Inc overvalued?
According to Wall Street analysts Oncternal Therapeutics Inc’s price is currently Undervalued.
Does Oncternal Therapeutics Inc pay dividends?
Oncternal Therapeutics Inc does not currently pay dividends.
What is Oncternal Therapeutics Inc’s EPS estimate?
Oncternal Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncternal Therapeutics Inc have?
Oncternal Therapeutics Inc has 2,959,645 shares outstanding.
What happened to Oncternal Therapeutics Inc’s price movement after its last earnings report?
Oncternal Therapeutics Inc reported an EPS of -$2.86 in its last earnings report, beating expectations of -$3.22. Following the earnings report the stock price went down -20.349%.
Which hedge fund is a major shareholder of Oncternal Therapeutics Inc?
Currently, no hedge funds are holding shares in ONCT
---
Oncternal Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.46%
12-Months-Change
Fundamentals
Return on Equity
-149.86%
Trailing 12-Months
Asset Growth
-63.88%
Trailing 12-Months
Company Description
Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.
---
ONCT Earnings Call
Q2 2024
0:00 / 0:00
---
ONCT Stock 12 Month Forecast
Average Price Target
$2.00
▲(75.44% Upside)
Technical Analysis
Aclaris Therapeutics
―
ADC Therapeutics
―
Aptevo Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering ONCT
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-80.16%
reiterated a buy rating 4 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -80.16% per trade.
---